New PET tracer could sharpen cancer detection
NCT ID NCT05641896
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan results with tissue samples. A total of 109 participants were enrolled, and the study has been completed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- [18F]FAPI-74 (a radioactive tracer for PET imaging)
- What this could lead to
- If successful, this imaging method could help doctors more accurately detect and locate gastrointestinal cancers, potentially guiding better treatment decisions.
- What could go wrong
- This is a phase 2 study with a moderate number of participants. The imaging agent may not prove more effective than current methods, and results may not apply to all cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
109 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Jun 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Confirmed diagnosis of gastrointestinal (GI) malignancy, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer * Available tissue sample obtained through biopsy or to be obtained through scheduled biopsy and/or surgical resection * No treatment received between tissue sample taken and \[18F\]FAPI-74 PET * Anatomic imaging (e.g., CT, MRI) obtained within ≤ 28 days of consent * Age ≥ 18 years * Completed informed consent as determined per the IRB of record Exclusion Criteria: * Pregnant as determined by a pregnancy test as per institutional guidelines for individuals of child-bearing potential * Declining to use effective contraceptive methods during the study (for individuals of child-producing potential) * Need for emergent surgery that would be delayed by participation * Bacterial, viral, or fungal infections requiring systemic therapy, that are expected to impact FAP expression in the opinion of the sponsor or their designee * Serious co-morbidities and serious nonmalignant disease (e.g., hydronephrosis, kidney failure, liver failure, systemic or local inflammatory or autoimmune diseases or other conditions) that in the opinion of the investigator, physician of record and/or Sofie could compromise subject safety and/or protocol objectives * Known diagnosis of an autoimmune disorder that is expected to impact FAP expression in the opinion of the sponsor or their designee * Patients receiving any other investigational agent within the past 28 days * Breastfeeding. Note: nursing parents are allowed if the potential participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the \[18F\]FAPI-74 injection * Known hypersensitivity to any excipients used in \[18F\]FAPI-74: trace amounts of sodium acetate, sodium ascorbate, ascorbic acid, ethanol, acetonitrile or AlCl. * Renal or liver function impairment\* \*Defined by liver impairments as AST\>3x the upper limit of normal, ALT\>3x the upper limit of normal, or bilirubin\>1.5x the upper limit of normal. Renal impairment as defined by a creatinine clearance of \>1.5x the upper limit of normal utilizing the Cockcroft Gault formula
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Massachusetts general hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55902, United States
-
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, New York, 10065, United States
-
Northwell Health
Lake Success, New York, 11042, United States
-
University of California Los Angeles (UCLA) Health
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sparing the liver: targeted chemoembolization meets lenvatinib in liver cancer
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- AI-Enhanced ultrasound aims to catch liver cancer earlier